Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
News|Podcasts|June 23, 2026
ACT Brief: ICON-Microsoft AI Partnership, DCT Site Burden, and AI-Enabled Neuroimmune Discovery
Author(s)Andy Studna, Senior Editor
In today's ACT Brief, we examine a major CRO-tech partnership scaling agentic AI, operational challenges sites face with decentralized trials, and AI-driven CNS drug discovery collaboration.
This is the Applied Clinical Trials Brief—your fast track to the latest insights shaping clinical operations and drug development.
- ICON named Microsoft as a preferred technology
partner to accelerate Orbis, ICON's agentic AI platform. The partnership combines Microsoft Fabric and Azure infrastructure with domain-specific agents embedded in trial workflows, spanning protocol digitization, site identification, monitoring, and patient engagement. - In Part 2 of her recent
interview with ACT at the 2026 DIA Global Annual Meeting, Joan Chambers, independent senior consultant at Tufts CSDD, examined operational challenges sites face implementing DCT components alongside traditional trial management. The industry remains in a learning phase where data will ultimately need to guide which modalities work best in which contexts. - Insilico Medicine and SK Biopharmaceuticals entered an R&D
collaboration on AI-enabled drug discovery in neuroimmune CNS disorders. Insilico's Pharma.AI platform will generate candidates while SK Biopharmaceuticals handles late-stage development and US commercialization, establishing a scalable platform for future CNS programs.
That's all for today's ACT Brief. Join us tomorrow for more updates shaping clinical operations and drug development. Thanks for listening.
Related to this article
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
In today's ACT Brief, we examine the FDA's multi-domain transparency priorities, why radiopharmaceutical trials need redesigned infrastructure, and how AI can make enrollment more predictable.
In today's ACT Brief, we examine FDA input sought on early-phase ibogaine protocols, why mixed outsourcing models spread faster than oversight infrastructure, and a major partnership for a rare kidney disease treatment.
In today's ACT Brief, we examine practical guidance for clinical operations teams beginning AI adoption, how hierarchical endpoints better reflect treatment benefit, and why early-stage program failures signal smarter pipeline management.
In today's ACT Brief, we examine how AI enables sponsors to pressure-test protocols before enrollment, HHS's multi-initiative effort to accelerate trial design and execution, and FDA approval expanding heart disease therapy to adolescents.
In today's ACT Brief, we examine AI's role as trial design advisor with human leadership, how to govern autonomous agents in regulated operations, and real-world outcomes from switching to oral weight-loss therapy.
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
3
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
4
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
5